Maxi Investments CY Ltd Makes New $966,000 Investment in uniQure N.V. $QURE

Maxi Investments CY Ltd purchased a new stake in uniQure N.V. (NASDAQ:QURE) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 40,000 shares of the biotechnology company’s stock, valued at approximately $966,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. IFP Advisors Inc lifted its position in shares of uniQure by 18.0% during the 3rd quarter. IFP Advisors Inc now owns 3,280 shares of the biotechnology company’s stock worth $79,000 after buying an additional 500 shares during the last quarter. Activest Wealth Management acquired a new stake in uniQure in the third quarter valued at about $121,000. Assenagon Asset Management S.A. boosted its stake in uniQure by 35.1% in the third quarter. Assenagon Asset Management S.A. now owns 693,693 shares of the biotechnology company’s stock valued at $16,760,000 after buying an additional 180,163 shares in the last quarter. Sanders Morris Harris LLC bought a new position in uniQure in the third quarter valued at about $468,000. Finally, Two Seas Capital LP bought a new position in uniQure in the third quarter valued at about $31,988,000. Institutional investors own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. Royal Bank Of Canada reduced their price target on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating on the stock in a research note on Friday, October 2nd. HC Wainwright restated a “buy” rating on shares of uniQure in a research note on Tuesday, September 29th. UBS Group reaffirmed a “buy” rating and set a $48.00 price target (up from $27.00) on shares of uniQure in a report on Thursday, October 15th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 price objective on shares of uniQure in a research report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.25.

uniQure Stock Down 3.5%

QURE opened at $21.65 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The company’s 50 day moving average price is $36.97 and its two-hundred day moving average price is $29.65.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The business had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same period in the previous year, the business posted ($0.69) EPS. As a group, sell-side analysts anticipate that uniQure N.V. will post -3.82 earnings per share for the current year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.